

Publications on FcRn Antagonists and Other Treatments for gMG

Resource	Address
Antozzi C, Vu T, Ramchandren S, et al. Safety and efficacy of nivalimab in adults with generalised myasthenia gravis (Vivacity-MG3): A phase 3, randomised, double-blind, placebo-controlled study. <i>Lancet Neurol.</i> 2025;24:105-116.	https://pubmed.ncbi.nlm.nih.gov/39862879/
Bril V, Drużdż A, Grosskreutz J, et al. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): A randomised, double-blind, placebo-controlled, adaptive phase 3 study. <i>Lancet Neurol.</i> 2023;22:383-394.	https://pubmed.ncbi.nlm.nih.gov/37059507/
Gerischer L, Doksani P, Hoffmann S, Meisel A. New and emerging biological therapies for myasthenia gravis: A focussed review for clinical decision-making. <i>BioDrugs.</i> 2025;39:185-213.	https://pubmed.ncbi.nlm.nih.gov/39869260/
Gilhus NE, Andersen H, Andersen LK, et al. Generalized myasthenia gravis with acetylcholine receptor antibodies: A guidance for treatment. <i>Eur J Neurol.</i> 2024;31:e16229.	https://pubmed.ncbi.nlm.nih.gov/38321574/
Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJGM. Myasthenia gravis. <i>Nat Rev Dis Primers.</i> 2019;5:30.	https://pubmed.ncbi.nlm.nih.gov/31048702/
Howard JF Jr, Bril V, Vu T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): A multicentre, randomised, placebo-controlled, phase 3 trial. <i>Lancet Neurol.</i> 2021;20:526-536.	https://pubmed.ncbi.nlm.nih.gov/34146511/
Narayanaswami P, Sanders DB, Wolfe G, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. <i>Neurology.</i> 2021;96:114-122.	https://pubmed.ncbi.nlm.nih.gov/33144515/
Roopenian DC, Akilesh S. FcRn: The neonatal Fc receptor comes of age. <i>Nat Rev Immunol.</i> 2007;7:715-725.	https://pubmed.ncbi.nlm.nih.gov/17703228/
Verity R, Narayanaswami P. Efgartigimod alfa-fcab use in a pregnant woman with generalized myasthenia gravis: A case report. <i>Muscle Nerve.</i> 2024;70:1272-1274.	https://pubmed.ncbi.nlm.nih.gov/39387228/

All URLs accessed October 30, 2025